JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects. In Vitro JC124 shows selective inhibition of NLRP3 inflammasome formation and activation of caspase-1, and reduction of IL-1β both in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Sprague-Dawley rats (3-4-months-old) bearing traumatic brain injury (TBI) Dosage: 100 mg/kg Administration: i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI Result: Significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. Form:Solid